Similarly, the treatment of mice with an alternative allosteric PTPN11 inhibitor, SHP099, resulted in enhanced T cell recruitment to orthotopic non-small cell lung carcinoma (NSCLC) nodules [53]. Here, PTPN11 is linked to non-small cell lung carcinoma.